History of Ä¢¹½ÊÓƵ
The Beginnings of Ä¢¹½ÊÓƵ
Ä¢¹½ÊÓƵ is a private Canadian Biotech company based in Calgary, Canada, with additional operations in Toronto, Canada. The Company was co-founded in 2015 by Brad Sorenson, Eric Marcusson, Ph.D. and Dr. Scott Leary, MD.
Brad Sorenson, previously a Co-founder of another mRNA therapeutics company focused on rare diseases, left to found Ä¢¹½ÊÓƵ after his 13-year-old son was diagnosed with late-stage glioblastoma. Brad recognized the need for a company that would focus on the potential of mRNA-based therapies for the prevention and treatment of cancers.
Ä¢¹½ÊÓƵ' Shift from Cancer to COVID-19 Vaccine Development
From its inception until the beginning of the COVID-19 pandemic in 2020, Ä¢¹½ÊÓƵ was focused on developing personalized cancer vaccines for glioblastoma and ovarian cancer. The Company was within months of launching its first phase 1 study in oncology when the pandemic hit
As the COVID-19 pandemic began, Ä¢¹½ÊÓƵ had the correct expertise and technology to produce a proprietary SARS-CoV-2 mRNA vaccine. We could quickly pivot and answer the call for a vaccine to treat this threat. The resulting PTX-COVID19-B mRNA-LNP vaccine successfully completed phase 1 and 2 results.
Ä¢¹½ÊÓƵ Covid-19-PTX-B Human Clinical Trial Results
A Platform for the Future of Ä¢¹½ÊÓƵ
Our Phase 2 human clinical trial was a comparator trial against the Pfizer/BioNTech Comirnaty® vaccine. The results of clinical trial data showed that our PTX-COVID-19 vaccine demonstrated a high level of safety as well as efficacy and immunogenicity, similar to the Pfizer/BioNTech vaccine. The PTX-COVID19-B vaccine has since been out-licensed to an external partner for further development.
Ä¢¹½ÊÓƵ exited the pandemic with much more than a COVID-19 vaccine; we came out with a full-fledged mRNA medicines ecosystem consisting of a proven mRNA platform, a next-generation LNP platform, and a robust manufacturing platform capable of personalized to pandemic scale manufacturing. We are now applying this platform across academic and industry partnerships to build a robust pipeline of assets for oncology, infectious diseases, and animal health applications.
Ä¢¹½ÊÓƵ mRNA Technology Platform
Ä¢¹½ÊÓƵ is the first mRNA Biotech company to have completed a clinical comparator trial against the Pfizer/BioNTech Comirnaty Covid vaccine.
Our proprietary mRNA vaccine, COVID-19 PTX-B, demonstrated high safety, efficacy and impressive immunogenicity.
Ä¢¹½ÊÓƵ mRNA Technology Platform
Ä¢¹½ÊÓƵ is the first mRNA Biotech company to have completed a clinical comparator trial against Pfizer/BioNTech Comirnaty Covid vaccine.
Our proprietary mRNA vaccine, COVID-19 PTX-B, demonstrated high safety, efficacy and impressive immunogenicity.